Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Share (Tables)

Earnings (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2020 and 2019 (in thousands except per share amounts):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
EPS Numerator:
Net income (loss)	$	(17,576)	$	(20,606)	$	3,667	$	(38,204)
EPS Denominator—Basic:
Weighted-average common shares outstanding		168,570		167,191		168,519		167,182
EPS Denominator—Diluted:
Weighted-average common shares outstanding		168,570		167,191		168,519		167,182
Dilutive effect of stock options and shares under ESPP		—		—		6		—
Weighted-average shares outstanding and common stock equivalents		168,570		167,191		168,525		167,182
Net income (loss) per common share, basic and diluted	$	(0.10)	$	(0.12)	$	0.02	$	(0.23)

Schedule of antidilutive securities

We had securities which could potentially dilute basic earnings per share, but were excluded from the computation of diluted earnings (loss) per share for all periods presented, as their effect would have been antidilutive. These securities consist of the following (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Outstanding stock options		27,598		25,050		26,536		25,050
Purchase Plan		344		332		—		201
Total		27,942		25,382		26,536		25,251